Efficacy of brain radiotherapy plus EGFR-TKI for
EGFR-mutated NSCLC patients who develop brain metastasis

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated NSCLC patients who develop brain metastasis

Bibliographic Details
Main Authors:	Wenxian Wang, Zhengbo Song, Yiping Zhang
Format:	Article
Language:	English
Published:	Termedia Publishing House 2018-10-01
Series:	Archives of Medical Science
Subjects:	brain metastases epidermal growth factor recptor tyrosine kinase inhibitors non-small cell lung cancer radiotherapy
Online Access:	https://www.termedia.pl/Efficacy-of-brain-radiotherapy-plus-EGFR-TKI-for-r-nEGFR-mutated-NSCLC-patients-who-develop-brain-metastasis,19,33964,1,1.html

Similar Items

First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis
by: Yaowen Song, et al.
Published: (2023-10-01)

Combined action of EGFR tyrosine kinase inhibitors and whole-brain radiotherapy on EGFR-mutated non-small-cell lung cancer patients with brain metastasis
by: Lu YY, et al.
Published: (2016-03-01)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
by: Yu Saida, et al.
Published: (2019-11-01)

Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study
by: He ZY, et al.
Published: (2019-03-01)

Clinical Predictive Factors associated with First Line EGFR-TKI Efficacy  in Advanced NSCLC Patients with EGFR Mutations
by: Minjiang CHEN, et al.
Published: (2019-02-01)

Targeting HER3 to overcome EGFR TKI resistance in NSCLC
by: Qiuqiang Chen, et al.
Published: (2024-01-01)

Continuous Vaginal Bleeding Induced By EGFR-TKI in Premenopausal Female Patients With EGFR Mutant NSCLC
by: Min Yu, et al.
Published: (2022-06-01)

Neoadjuvant EGFR-TKI Therapy for EGFR-Mutant NSCLC: A Systematic Review and Pooled Analysis of Five Prospective Clinical Trials
by: Li Sun, et al.
Published: (2021-01-01)

Chemotherapy outcomes in EGFR‐TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study
by: Chien‐Yu Lin, et al.
Published: (2023-07-01)

Consensus on Application of Third-generation EGFR-TKI in EGFR Mutated NSCLC  (2022 Version)
by: Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee, et al.
Published: (2022-09-01)

Combination of Whole-Brain Radiotherapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Improves Overall Survival in EGFR-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases
by: Chien-Hung Chen, et al.
Published: (2019-07-01)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
by: Xuan Zhu, et al.
Published: (2019-10-01)

Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
by: Zhengyu Yang, et al.
Published: (2021-08-01)

Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy
by: Shujie Zhou, et al.
Published: (2022-09-01)

Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System  Metastases from Non-small Cell Lung Cancer
by: Yinghua JIN, et al.
Published: (2016-08-01)

EGFR-mutation testing and TKI treatment patterns in locally advanced and metastatic NSCLC in Norway – A nationwide retrospective cohort study
by: Åslaug Helland, et al.
Published: (2022-01-01)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
by: Guo-Hao Xia, et al.
Published: (2014-12-01)

Assessing EGFR‐mutated NSCLC with bone metastasis: Clinical features and optimal treatment strategy
by: Wei‐Chun Chen, et al.
Published: (2024-04-01)

Local Treatment Combined with EGFR-TKIs for Advanced Non-small Cell Lung Cancer with Solitary Progression during EGFR-TKI Treatment
by: Xin ZHANG, et al.
Published: (2013-10-01)

Effect of Different Timing of Local Brain Radiotherapy on Survival of EGFR-Mutated NSCLC Patients with Limited Brain Metastases
by: Yu Wang, et al.
Published: (2023-09-01)

Clinical Observation of EGFR-TKI as A First-line Therapy on Advanced Non-small Cell Lung Cancer
by: Jianjie LI, et al.
Published: (2012-05-01)

Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models
by: Yuhan Zhang, et al.
Published: (2021-09-01)

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
by: Hou H, et al.
Published: (2019-06-01)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
by: Lihao Zhao, et al.
Published: (2019-12-01)

Identification of Targetable Liabilities in the Dynamic Metabolic Profile of <i>EGFR</i>-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance
by: Anastasios Gkountakos, et al.
Published: (2022-01-01)

Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance  in Lung Cancer
by: Qicheng ZHANG, et al.
Published: (2016-09-01)

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wen-Shuo Wu, et al.
Published: (2014-06-01)

Front-Line ICI-Based Combination Therapy Post-TKI Resistance May Improve Survival in NSCLC Patients With EGFR Mutation
by: Tian Tian, et al.
Published: (2021-11-01)

Concurrent Afatinib and Whole-Brain Radiotherapy in Exon 19-del-EGFR Mutant Lung Adenocarcinoma: A Case Report and Mini Review of the Literature
by: Chukwuka Eze, et al.
Published: (2017-05-01)

Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis
by: Limin CHEN, et al.
Published: (2019-05-01)

Complete Remission of Brain Metastases in Non-Small Cell Lung Cancer Patients Harboring an EGFR Mutation Treated with Tyrosine Kinase Inhibitor without Radiotherapy: A Report of 3 Cases
by: Yun Hwa Jung, et al.
Published: (2014-03-01)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01)

Preliminary Study of Differentially Expressed Serum Peptides of Advanced NSCLC Patients Responsive to EGFR-TKI and Their Clinical Significance
by: Zihe WANG, et al.
Published: (2016-09-01)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

Survival and intracranial control outcomes of whole-brain radiotherapy (WBRT) alone versus WBRT plus a radiotherapy boost in non-small-cell lung cancer with brain metastases: a single-institution retrospective analysis
by: Lu F, et al.
Published: (2019-05-01)

Diverse Mechanisms of Resistance against Osimertinib, a Third-Generation EGFR-TKI, in Lung Adenocarcinoma Cells with an <i>EGFR</i>-Activating Mutation
by: Shigetoshi Nishihara, et al.
Published: (2022-07-01)

Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance
by: Yujing Li, et al.
Published: (2023-05-01)

Rational application of EGFR-TKI adjuvant therapy in patients with completely resected stage IB-IIIA EGFR-mutant NSCLC: a systematic review and meta-analysis of 11 randomized controlled trials
by: Shu-Ling Zhang, et al.
Published: (2023-08-01)

Examining the Effect of ALK and EGFR Mutations on Survival Outcomes in Surgical Lung Brain Metastasis Patients
by: Sneha Sai Mannam, et al.
Published: (2023-09-01)

Risk Stratification Using a Novel Nomogram for 2190 EGFR-Mutant NSCLC Patients Receiving the First or Second Generation EGFR-TKI
by: John Wen-Cheng Chang, et al.
Published: (2022-02-01)